It aims to revolutionize microbial detection by developing novel metagenomic Next-Generation Sequencing (mNGS) solutions that allow for fast, accurate and cost-effective analyses. With its MPSeq mNGS platform, Agenmic enables a sample-to-result integrated workflow that takes the user from a primary sample to quantitative results for over 20,000 pathogens within 24 hours. Additionally, Agenmic's TPSeq tNGS platform can identify over 300 infectious agents and associated antibiotic resistance genes.
As a wholly-owned subsidiary of Agene, a biomedical high-tech company established in 2017, Agenmic benefits from Agene's mission to apply ultra-sensitive genetic testing technologies in clinical settings. Agene is committed to improving the detection and identification of pathogens to advance the development of precision medicine in infectious diseases.
At Agenmic, we are dedicated to pushing the boundaries of microbial detection with innovative solutions. Our MPSeq and TPSeq platforms are just the beginning of our commitment to revolutionize microbial detection and make a positive impact on public health.
With 8 large medical laboratories in China, all of our products have been extensively tested and proven to deliver reliable and accurate results.